Because wild-type p53 is an efficient promoter of apoptosis and senescence [145] in tumor cells, reactivating wild-type characteristics of p53 mutants, which are commonly overexpressed in cancer, is a viable therapeutic strategy. This evidence concerns the gene TP53 and cancer.